lintuzumab

{
  "id": "MLC-T-ONC-004852",
  "term": "lintuzumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of myelodysplastic syndromes and some types of leukemia. It binds to CD33, a protein on the surface of certain normal blood stem cells and some abnormal blood cells. It causes the immune system to kill these cells. Lintuzumab is a type of monoclonal antibody. Also called MoAb HuM195 and monoclonal antibody HuM195.",
    "A humanized recombinant monoclonal antibody directed against CD33, a cell surface antigen found on myeloid leukemia blasts and early hematopoietic progenitor cells. Lintuzumab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing CD33, resulting in a decrease in tumor burden. The humanized version of this monoclonal antibody exhibits less immunogenicity and improved binding affinity compared to its murine counterpart."
  ],
  "abbreviation": "MOAB HuG1-M195",
  "synonyms": [
    "MoAb HuM195",
    "monoclonal antibody HuM195",
    "Hu-M195 monoclonal antibody",
    "HuG1-M195",
    "HuG1-M195 monoclonal antibody"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lintuzumab/"
}